Clareo Health | A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
Participant has provided written informed consent and agrees to comply with the study protocol.
Participant with PBC diagnosis.
Participant for whom the treating physician has decided to start or participants who are currently receiving treatment with commercialized elafibranor.
If a participant has a caregiver who agrees to complete the caregiver questionnaires, an informed consent should be collected from the caregiver before any data is collected.
You may not be if
Participant is currently participating or, plans to participate in an investigational drug study or medical device study containing active substance.
Participant with known hypersensitivity to the product or to any of its excipients.
Participant with mental instability or incompetence, such that the validity of informed consent or ability to be compliant with the study is uncertain.
